Psoriasis is a chronic immune-mediated inflammatory skin disease marked by accelerated keratinocyte turnover and recurrent erythematous scaly plaques.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
Takeda shares came under valuation scrutiny after recent gains and mixed pipeline news, including a DNL593 collaboration exit and positive Phase 3 data for zasocitinib. The analyses said the stock was trading close to or above widely followed fair value estimates, while DCF assumptions pointed to much higher implied value.
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
The FDA is expected to issue draft guidance reducing testing requirements for biosimilar drugs, potentially lowering development costs by USD 20 million. The move comes as the biosimilars market shows strong growth, with major launches in 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07582783 |
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania |
NOT_YET_RECRUITING | |
| NCT07552792 |
Impact of Hand Rub Placement on Patient Trust and Disease Stigma |
NOT_YET_RECRUITING | NA |
| NCT07549828 |
Sebum Metabolomics and Lipidomics for Clinical Applications |
NOT_YET_RECRUITING | NA |
| NCT07532486 |
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis |
RECRUITING | NA |
| NCT07498543 |
Impact of Clinical and Psychological Factors on Satisfaction With Treatment in Psoriatic Patients on Biological Therapy |
COMPLETED | |
| NCT07494396 |
An AI-Based Erythema Measurement System for Psoriasis Lesions |
NOT_YET_RECRUITING | |
| NCT07489885 |
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07487831 |
The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease |
NOT_YET_RECRUITING | PHASE4 |
| NCT07485764 |
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07481019 |
A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology |
NOT_YET_RECRUITING | NA |
